|
May 15
|
Ionis to host 2024 virtual Annual Meeting of Stockholders
|
|
May 9
|
The Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
|
|
May 9
|
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
|
|
May 8
|
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
|
|
May 8
|
Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 8
|
Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
May 8
|
Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
|
|
May 7
|
Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
May 7
|
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Ionis reports first quarter 2024 financial results
|
|
May 6
|
Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
|
|
May 1
|
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
Apr 30
|
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
|
Apr 25
|
Ionis Publishes 2023 Corporate Responsibility Report
|
|
Apr 23
|
Ionis to hold first quarter 2024 financial results webcast
|
|
Apr 7
|
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
|
|
Mar 28
|
Ionis to hold olezarsen Phase 3 data webcast
|
|
Mar 25
|
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
|
|
Mar 25
|
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
|